An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
Condition(s):Colorectal CancerLast Updated:April 25, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Colorectal CancerLast Updated:April 25, 2017Completed
Condition(s):HER2-positive Metastatic Breast Cancer; First-line TreatmentLast Updated:February 26, 2024Recruiting
Condition(s):Type 2 DiabetesLast Updated:August 24, 2023Recruiting
Condition(s):First-line Treatment of HER2-positive Recurrent or Metastatic Breast CancerLast Updated:May 1, 2023Not yet recruiting
Condition(s):Lung CancerLast Updated:March 7, 2017Completed
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:January 5, 2022Completed
Condition(s):Acute GVH DiseaseLast Updated:November 16, 2022Active, not recruiting
Condition(s):Digestive System NeoplasmsLast Updated:September 11, 2023Recruiting
Condition(s):AdenocarcinomaLast Updated:June 14, 2017Completed
Condition(s):Metastatic Colorectal Cancer; RAS Wild-typeLast Updated:August 14, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.